Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.
Sibylle C MellinghoffSandra RobrechtRosanne SpruteLeonie MayerLeonie M WeskammChristine DahlkeHenning GruellFinn TeipelHans Anton SchlößerKlara SiepmannMartin ThelenAnna-Maria FinkKirsten FischerFlorian KleinMarylyn Martina AddoAndroniki KolovouOliver Andreas CornelyBarbara EichhorstMichael HallekPetra LangerbeinsPublished in: European journal of haematology (2024)
Our data reveal an increase of cellular and humoral immune response in CLL patients after fourth COVID-19 vaccination combined with SARS-CoV-2 infection, even in those undergoing B cell-depleting treatment. Patients with prior vaccination failure now show a specific IgG response. Future research should explore the duration and effectiveness of hybrid immunity considering various factors like past infection and vaccination rates, types and numbers of doses, and emerging variants.
Keyphrases
- sars cov
- chronic lymphocytic leukemia
- immune response
- end stage renal disease
- respiratory syndrome coronavirus
- ejection fraction
- newly diagnosed
- randomized controlled trial
- coronavirus disease
- chronic kidney disease
- systematic review
- peritoneal dialysis
- genome wide
- prognostic factors
- copy number
- dendritic cells
- gene expression
- dna methylation
- deep learning
- current status
- smoking cessation